AKT1 and glioblastoma: has confirmed that epidermal growth factor receptor mutation (EGFRvIII)‐activated mTORC2 signalling promotes GBM proliferation and chemotherapy resistance through the Akt‐independent activation of the NF‐κB pathway.22